Knight Therapeutics Inc. (TSE:GUD) Insider Sells C$1,839,000.00 in Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 300,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00.

Knight Therapeutics Stock Down 1.8 %

Knight Therapeutics stock opened at C$5.91 on Tuesday. The business has a fifty day moving average of C$5.73 and a two-hundred day moving average of C$5.69. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. The firm has a market cap of C$598.15 million, a P/E ratio of -29.55, a P/E/G ratio of -1,013.50 and a beta of 0.48. Knight Therapeutics Inc. has a twelve month low of C$4.35 and a twelve month high of C$6.23.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, August 8th. The company reported C($0.02) EPS for the quarter, missing the consensus estimate of C$0.03 by C($0.05). Knight Therapeutics had a negative net margin of 6.28% and a negative return on equity of 2.70%. The business had revenue of C$95.57 million for the quarter, compared to analysts’ expectations of C$89.83 million. On average, analysts forecast that Knight Therapeutics Inc. will post 0.1077501 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GUD shares. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th. Stifel Nicolaus upgraded Knight Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from C$5.75 to C$6.75 in a report on Tuesday, August 13th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.